Please assess the completion status of the following clinical trial:

Trial Title: Aspirin in Patients With Myocardial Infarction and Thrombocytopenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Presenting for Cardiology consult at M.D. Anderson Cancer Center.~2. Platelet count between 100,000 and 20,000.~3. Acute Coronary Syndrome diagnosed with their first 12 lead EKG.~4. Patients that continue to show evidence of MI by cardiac enzymes with CPK levels \> 2 normal limits, CK-MB levels 10% above normal limits, and Troponin I levels \> 1.4ug/L will be considered positive for MI.~5. Ability to give consent.~Exclusion Criteria:~1. Contraindications to aspirin including severe intolerance or true allergy, active bleeding, hemophilia, active retinal bleeding, severe untreated hypertension, active peptic ulcer, or other significant source of gastrointestinal or genitourinary bleeding, brain metastasis, and altered mental status.~2. Unwillingness or inability to give consent.~3. Progressive heart failure, unstable angina not responding to medical therapy for 24 hours, or ventricular tachycardia, necessitating thrombolysis, and angioplasty.~4. Patients that rule out for MI by cardiac enzymes panel after the first 24 hours.~5. Patients that rule in for MI and have Platelet count \> 100,000.~6. Patients with platelet count \< 20,000.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).